Furthermore, the phase I study has verified that APR-246 is safe at predicted therapeutic plasma levels with a favorable pharmacokinetic profile, and most importantly, can induce considerable p53-dependent biological effects in cancer patients with p53 mutations (91, 92). This evidence concerns the gene TP53 and cancer.